Single vs. Group CAPA-IVM Culture of Cumulus-oocyte Complexes

July 23, 2023 updated by: Mỹ Đức Hospital

Effect of Single vs. Group CAPA-IVM Culture of Human Cumulus-oocyte Complexes From Small Antral Follicles in a SIBLING Oocyte Study Design

Oocyte in vitro maturation (IVM) is a minimal-stimulation ART with reduced hormone-related side effects and risks for the patients. However, the approach is not widely used because of an efficiency gap compared to conventional ART. In order to further optimize and adapt the CAPA-IVM system in the IVM clinic, this pilot study aims to check the feasibility of applying a single COC CAPA-IVM strategy versus the group COC culture CAPA-IVM

Study Overview

Status

Completed

Conditions

Detailed Description

Oocyte in vitro maturation (IVM) is a minimal-stimulation ART with reduced hormone-related side effects and risks for the patients. However, the approach is not widely used because of an efficiency gap compared to conventional ART.

Oocytes retrieved for IVM procedures derive from a heterogeneous pool with variable cellular and molecular characteristics that indicate its immature status. Thus, in vitro systems that permit and enhance acquisition and synchronization of meiotic competence (ability to resume meiosis in response to an ovulatory stimulus) and developmental competence (ability to be fertilized and support early embryo development) before the meiotic trigger are crucial for the optimization of human IVM systems.

A novel two-step IVM culture system (named CAPA-IVM) involving a pre-maturation culture with C-type natriuretic peptide (CNP) and a maturation step in presence of Amphiregulin (AREG), both more physiological compounds improving oocyte competence, have been introduced in previous clinical studies. So far these pilot studies proved to increase the rates of oocyte maturation, good quality embryos on day 3, good quality blastocyst, and as a result a higher embryo yield. CAPA-IVM blastocysts have shown similar rates of methylation and gene expression at gDMRs compared to COS embryos; and the expression of ma-jor epigenetic regulators was similar between both groups. Furthermore, an improvement in pregnancy rates strengthens the clinical relevance of the use of CAPA-IVM strategy.

In order to further optimize and adapt the CAPA-IVM system in the IVM clinic, this pilot study aims to check the feasibility of applying a single COC CAPA-IVM strategy versus the group COC culture CAPA-IVM. A single COC culture would permit to perform a non-invasive molecular analysis per matured oocyte, in order to identify quality genes ex-pressed in cumulus cells post-IVM (cumulus biomarkers), which could be subsequently used to identify the embryo(s) with highest potential of implantation.

Study Type

Interventional

Enrollment (Actual)

15

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Ho Chi Minh City, Vietnam
        • My Duc Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 37 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Having polycystic ovarian morphology: at least 25 follicles (2-9 mm) throughout the whole ovary and/or increased ovarian volume (>10ml) (it is sufficient that 1 ovary fits these criteria)
  • No major uterine or ovarian abnormalities
  • Having at least 15 follicles on the OPU day
  • Patients consent to participate in the study

Exclusion Criteria:

  • High (>grade 2) grade endometriosis
  • Cases with extremely poor sperm (serve OAT: density <1 million, mobility <10% and sperm from testicular surgery)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Single Culture
Transfer the COCs cultured individually in Capacitation medium to the individual washing droplets from the "washing dish" containing "Maturation Medium" and wash them thoroughly. Then transfer COCs one by one to the "Culture dish" with "Maturation Medium".
Cumulus-oocyte complexes (COC) will be cultured in CAPA-IVM standard conditions: 24 hrs capacitation followed by 30h maturation. The first group will be culture in pools (group culture). The second group will be culture individually in 20µl droplets.
Experimental: Group Culture
Transfer half of the COCs (5-10 at a time) from the Capacitation culture dish to the "washing dish" containing "Maturation Medium (Group Culture)" by using an Eppendorf micropipette and wash them thoroughly (load pipette tips with 5µl, max. 10µl). Then transfer COCs to the "IVM dish" with "Maturation Medium (Group Culture)".
Cumulus-oocyte complexes (COC) will be cultured in CAPA-IVM standard conditions: 24 hrs capacitation followed by 30h maturation. The first group will be culture in pools (group culture). The second group will be culture individually in 20µl droplets.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of good quality embryos
Time Frame: At least 3 days after intra-cytoplasmic sperm injection
Number of good quality Day 3 embryos obtained
At least 3 days after intra-cytoplasmic sperm injection

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Multiple delivery
Time Frame: At 24 weeks' gestation
Birth of more than one baby beyond 24 weeks
At 24 weeks' gestation
Maturation rate
Time Frame: Two days after oocytes pick-up
Percentage of mature oocytes by 2 types of COC culture
Two days after oocytes pick-up
Fertilization rate
Time Frame: 16-18 hours after intra-cytoplasmic sperm injection
Percentage of fertilized oocytes by 2 types of COC culture
16-18 hours after intra-cytoplasmic sperm injection
Cleavage rate
Time Frame: At least 3 days after intra-cytoplasmic sperm injection
Percentage of day-3 embryos over fertilized oocytes by 2 types of COC culture
At least 3 days after intra-cytoplasmic sperm injection
Expansion rate
Time Frame: After at least 30 hours of maturation culture
Percentage of cumulus-oocyte complexes expanded after culture by 2 types of COC culture
After at least 30 hours of maturation culture
The relative expression ratio ( R ) of human cumulus cell genes
Time Frame: cumulus cells will be collected after at least 30 hours of maturation culture, storaged at -80oC until RNA purification
Cumulus cells will be collected, cDNA synthesis after mRNA purification, relative quantification PCR for detecting gene expression
cumulus cells will be collected after at least 30 hours of maturation culture, storaged at -80oC until RNA purification
Clinical pregnancy
Time Frame: 5 weeks after embryo placement after the completion of the first transfer
at least one gestational sac on ultrasound at 7 weeks' gestation with the detection of heart beat activity
5 weeks after embryo placement after the completion of the first transfer
Implantation rate
Time Frame: 3 weeks after embryo transferred after the completion of the first transfer
as the number of gestational sacs per number of embryos transferred
3 weeks after embryo transferred after the completion of the first transfer
Ongoing pregnancy
Time Frame: At 12 weeks' gestation
Ongoing pregnancy is defined as pregnancy with detectable heart rate at 12 weeks' gestation or beyond, after the completion of the first transfer
At 12 weeks' gestation
Miscarriage
Time Frame: at 24 weeks of gestation after the completion of the first transfer
pregnancy loss at < 24 weeks
at 24 weeks of gestation after the completion of the first transfer
Multiple pregnancy
Time Frame: 5 weeks after embryo placement after the completion of the first transfer
Defined as presence of more than one sac at early pregnancy ultrasound (6-8 weeks gestation)
5 weeks after embryo placement after the completion of the first transfer
Positive pregnancy test
Time Frame: at 2 weeks after the embryo placement after the completion of the first transfer
Serum human chorionic gonadotropin level greater than 25 mIU/mL
at 2 weeks after the embryo placement after the completion of the first transfer
Live birth
Time Frame: At 24 weeks of gestation
defined as at least one newborn after 24 weeks of gestation and exhibiting any sign of life; twins were counted as a single birth
At 24 weeks of gestation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Tuong M Ho, MD, MCE, Hope Research Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2020

Primary Completion (Actual)

November 30, 2020

Study Completion (Actual)

October 24, 2021

Study Registration Dates

First Submitted

September 5, 2020

First Submitted That Met QC Criteria

September 23, 2020

First Posted (Actual)

September 24, 2020

Study Record Updates

Last Update Posted (Actual)

July 25, 2023

Last Update Submitted That Met QC Criteria

July 23, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • 13/20/DD-BVMD

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on PCOS

Clinical Trials on The way of Cumulus-oocyte complexes (COC) culture

3
Subscribe